A new study finds that, overall, lifespan for those living with Parkinson’s disease (PD) is nearly identical to those in the general population. The study looked at a group of diseases called synucleinopathies, including Parkinson’s. The results appear in the May 15 online edition of JAMA Neurology.
Overall, the study reminds us that people with Parkinson’s can live many years with the disease. With that in mind, people living with these diseases, their care partners and their families can take steps to plan for their health care and make important financial decisions.
The Vatican this week marks the fifth anniversary of Pope John Paul II’s death amid some doubts that the miracle needed for his saint-making cause will stand up to scrutiny and questions about his record combating pedophile priests.
VATICAN CITY, March 5 (UPI) — A French nun’s return to illness could delay the canonization of Pope John Paul II.
Pope Benedict XVI put his predecessor on the fast track for sainthood almost immediately, and there had been speculation John Paul would be beatified on Oct. 16, the anniversary of his election to the papacy, the Guardian reports. The Vatican has now scheduled the canonization of six saints on Oct. 17, which would bar a beatification the day before.
To become a saint requires evidence of posthumous miracles. Sister Marie Simon-Pierre said three years ago she had been relieved of the symptoms of Parkinson’s disease after praying to John Paul, who also suffered from Parkinson’s.
Now, a Polish newspaper, Rzeczpospolita, reports Simon-Pierre’s symptoms have returned. The newspaper also said her doctor, on his Web site, suggested she did not suffer from Parkinson’s but from a disease with the same symptoms that is known to go into remission.
New evidence suggests being hungry isn’t a bad thing, at least for your brain.
When the “hunger hormone” ghrelin was first discovered in 1996, scientists were excited about its future application the treatment of eating disorders. Years of research revealed that the hormone, which is produced in an empty stomach, stimulates appetite and regulates the distribution and rate of use of energy.
But now, at Swansea University in the United Kingdom, Jeffery Davis and his team added ghrelin to lab-grown mouse brain cells and found that it activated neurogenesis—the process by which neurons divide and multiply. This work could revolutionize how we treat neurodegenerative conditions like Parkinson’s disease.
Scientists have discovered that ghrelin, known as the “hunger hormone,” activates the process by which cells divide and multiply—offering a possible treatment for Parkinson’s disease.
Parkinson’s disease is a long-term disorder of the central nervous system that primarily affects the motor system. Scientists don’t know the cause of the disease, but it’s believed to be a result of a loss of type of brain cell. But some research, even some conducted by Davis, suggests ghrelin could play a part in treating it. Here’s Clare Wilson, writing for New Scientist:
In further experiments, Davies’s team found that ghrelin protects brain cells in a dish from dying when they are encouraged to mimic Parkinson’s disease. And Davies’s colleague Amanda Hornsby found that, in a study of 28 volunteers, people with Parkinson’s dementia—cognitive impairment caused by Parkinson’s disease—have lower levels of ghrelin in their blood than people who don’t have the condition.
This indicates that in the future, ghrelin could be used to treat Parkinson’s dementia. From an evolutionary perspective, the link between ghrelin and mental ability makes sense. If an animal is hungry, it needs extra brainpower to find that vital next meal. Previous studies on mice showed that a reduced-calorie diet helped boost the number of neural connections in their brain and they performed better on learning and memory tests.
The American Medical Association stated in a 2007 online report, “Medical Marijuana (A-01)”:
Only limited data exist on the effects of marijuana in patients with Tourette’s syndrome who respond inadequately to standard treatment, consisting of 4 case histories that report beneficial effects of smoked marijuana and 1 who reported substantial benefit from oral 9-THC.
The Institute of Medicine published in its March 1999 report titled, “Marijuana and Medicine: Assessing the Science Base”:
It is important to note that stress and anxiety tend to worsen the symptoms of movement disorders. Thus, marijuana’s calming effect could be a primary reason why some patients claim that it brings them relief.
Movement Disorders stated in a Sep. 2004 article titled, “Survey on Cannabis Use in Parkinson’s Disease” by researchers from the Movement Disorders Centre at the Department of Neurology at Charles University, Prague, Czech Republic:
An anonymous questionnaire sent to all patients attending the Prague Movement Disorder Centre revealed that 25% of 339 respondents had taken cannabis and 45.9% of these described some form of benefit. …The late onset of cannabis action is noteworthy. Because most patients reported that improvement occurred approximately two months after the first use of cannabis, it is very unlikely that it could be attributed to a placebo reaction.
Desired Strains Effects and Administration Methods
Patients suffering from movement disorders should consider the indica cannabis strains with high CBD low THC that provide following palliative effects:
Always seek the advice of your physician or other qualified healthcare provider before starting any new treatment or discontinuing an existing treatment with medicinal cannabis. Talk with your healthcare provider about any
For your physician
Only physicians, nurse practitioners and physician’s assistants are allowed to recommend medical marijuana.
Recommending physicians must:
Be licensed and practicing in New York
Be qualified to treat the serious condition
Have complete the New York Department of Health-approved training course
Have registered with the DOH
Must be caring for the patients for whom they are making recommendations for, meaning that they have done a full assessment of the patients’ medical histories, current medical conditions and believe that the patient will benefit from the use of medical marijuana.
Must consult the prescription drug monitoring program and review the patient’s control substances history before issuing a recommendation
should not be used as a substitute for the care and knowledge that your physician can provide.
How to use
Start Low and Go Slow
The basic principal for dosing medical marijuana is to start with a low dose and to go slow in taking more until the effect of the first dose is fully realized, because the effects of cannabis are not always immediately felt. Starting low and going slow allows patients to accommodate for the different experiences they may have.
Cannabis has a wide margin of safety and there is limited risk of overdose. However, caution is warranted until a patient fully understands the effect that the cannabis may have. Dosage varies greatly among patients, even when treating the same condition.
There are many factors that impact the effect, including:
Amount used (dosage)
Strain used and method of consumption
Experience and history of cannabis use
Mindset or mood
Nutrition or diet
All allowable forms of medical marijuana, including methods of consumption and strain, variety, and strength, are determined by the Commissioner and must be approved by the Commissioner before they can be sold. Smoking as a method of consumption of the only form not left to the Commissioner and specifically excluded from ‘certified medical use’ in the statute.
Battery-powered handheld vaporizer
Disposable handheld vaporizer with replacement cartridge options
Electric vaporizing device
Metered-dose inhalers (MDI)
Effects of Medical Marijuana
Short-Term Cognitive Effects
Patients should be aware that cannabis use causes short-term impairments in the following brain functions:
Sense of time
Cannabis users may “pull themselves together” to concentrate on simple tasks for brief periods of time. That said, performance impairments may be observed for at least one to two hours following cannabis use, and residual effects have been reported up to 24 hours depending on potency of the cannabis, the method of administration, and the tolerance of the user.
Long-Term Cognitive Effects
Consult the advice of your physician if you are a long-term user of medical cannabis and intend to stop using it, or if you are concerned about dependence on or addiction to cannabis. Your physician can help you manage any withdrawal effects that you may experience. Always seek the advice of your physician or other qualified healthcare provider before starting any new treatment or discontinuing an existing treatment with medical cannabis.
Talk with your healthcare provider about any questions you may have regarding your cannabis use. The information and materials provided to you by PharmaCannis should not be used as a substitute for the care and knowledge that your physician can provide to you.
Each registered organization may initially produce up to five brands of medical marijuana product, with prior approval of the Department, which must include at least one brand that has a low tetrahydrocannabinol (THC) content and high cannabidiol (CBD) content, and at least one brand with approximately equal amounts of THC and CBD. Each brand in its final form must have a consistent cannabinoid profile. Independent laboratory testing of the final medical marijuana product is required to test for contaminants and ensure product consistency.
Until independent laboratories receive certification from the New York State Environmental Laboratory Approval Program (ELAP), the Department’s Wadworth Center Laboratory will perform the testing and analysis of final medical marijuana products. Each registered organization may have up to four dispensing facilities, owned and operated by the registered organization, where approved medical marijuana products will be dispensesd to certified patients or their designated caregivers, who have registered with the Department. Dispensing facilities must report dispensing data to the New York State Prescription Monitoring Program Registry and consult the registry prior to dispensing approved medical marijuana products to certified patients or their designated caregivers.
Frequently Asked Questions
You can find a list of commonly asked questions for the New York Medical Marijuana Program here.
If you have Parkinson’s disease, you are likely to feel stress related to your tremors. Sometimes, you may feel self-conscious. That alone is stressful. These simple relaxation solutions open up natural relaxation responses which can help improve your mood and ease your mind.
The National Institutes of Health (NIH) considers relaxation exercises to be safe for most people. However, just like with exercise routines, people with serious physical health problems such as Parkinson’s should discuss the techniques with their healthcare provider before starting a relaxation routine.
There are many viable techniques for relaxing. These include deep breathing exercises, self-hypnosis, and guided imagery. Each relaxation technique goal is to produce a natural reaction from the body. This should include: lower blood pressure, slower breathing, and a sense of well-being.
We found five easy relaxation exercises that are simple enough for most people to do1 in a chair or while lying in bed.
Place your hand just beneath your navel so you can feel the gentle rise and fall of your belly as you breathe. Breathe in. Pause for a count of three. Breathe out. Pause for a count of three. Continue to breathe deeply for one minute, pausing for a count of three after each inhalation and exhalation.
While sitting comfortably, take a few slow deep breaths and quietly repeat to yourself, “I am” as you breathe in and, “at peace” as you breathe out. Repeat slowly two or three times. Then, feel your entire body relax into the support of your chair.
Raise eyebrows up and tense the muscles across the forehead and scalp. Feel the tension build and hold. Take a deep breath. As you exhale say “relax” while letting the tension leave your body.
Relax your facial muscles and allow your jaw to open slightly. Let your shoulders drop. Let your arms fall to your sides. Allow your hands to loosen so there are spaces between your fingers. Uncross your legs or ankles. Feel your thighs sink into your chair, letting your legs fall comfortably apart. Feel your shins and calves become heavier and your feet grow roots into the floor. Now, breathe in slowly and breathe out slowly.
Observe your abdomen rising and falling with each breath. Inhale and press your navel toward the spine then tense your abdomen. Feel the tension build and hold it. Take in a deep breath. As you exhale say “relax,” and let the tension leave you.
The NIH recognizes the relaxation response as having broad health benefits including the reduction of pain and restoration of sleep. In addition, research on the relaxation response has shown that this simple technique can increase energy and decrease fatigue. It can increase motivation, productivity, and improve decision-making ability, too. The relaxation response lowers stress hormone levels and lowers blood pressure.
The relaxation response is your personal ability to make your body release chemicals and brain signals that make your muscles and organs slow down and increase blood flow to the brain. We hope these stress relieving solutions help you find a relaxation routine that suits you so that you will continue to practice it each day.
The fourth and last patient of the first group in a clinical trial of stem cell transplants in Parkinson’s disease has successfully received the transplant, the International Stem Cell Corporation (ISCO) reported. Researchers are now preparing for the next stage, in which patients will receive a higher number of cells.
So far, researchers have not recorded any adverse events among the four patients who had neural stem cells, called ISC-hpNSC, inserted into their brains.
If successful, the stem cell therapy has the potential to regenerate lost nerve cells — and revolutionize the way Parkinson’s disease is treated.
“We are very encouraged by the early clinical safety data for ISC-hpNSC,” Russell Kern, PhD, executive vice president and chief scientific officer of ISCO, said in a news release.
The Phase 1 clinical trial (NCT02452723) was launched in March 2016, and expects to enroll 12 patients with moderate Parkinson’s disease. Patients are divided into three groups of four patients each. The groups will receive increasing doses, ranging between 30,000,000 to 70,000,000 neural stem cells.
The main goal of the trial is to assess the safety of the treatment, with patients followed for 12 months after the transplants.
But researchers will also use brain scans to assess whether the cells survive once transplanted, and if they contribute to making the patients better. Participants are assessed using the Unified Parkinson Disease Rating Scale (UPDRS) and other tools, and although the study is small, researchers will evaluate any potential improvements in symptoms.
Parkinson’s symptoms typically appear when a large proportion of brain cells containing dopamine are already gone. And while treatments with added dopamine may improve symptoms, at least for some time, the treatment approach is fraught with dosing difficulties.
The ISC-hpNSC cells are derived from what researchers call human parthenogenetic stem cells. Parkinson’s animal models that received the treatment improved, making researchers and patients alike hope that the same will be seen in patients.
The cells are thought to provide neurotrophic support to brain cells still alive. This means they secrete factors that help dying neurons survive. They are also thought to replace the dead and dying dopamine neurons.
But as the trial started, researchers raised concerns that not enough was known about what the cells do in the brain. The group of researchers also questioned whether the safety follow-up of one year was sufficient, and argued that clinical trials of stem cell approaches may be a premature step, in an article in the Journal of Parkinson’s Disease.
Still, ISCO has an optimistic view of the trial continuation.
“We look forward to dosing our second cohort with 50 million cells and enrolling the rest of our clinical trial participants in 2017,” Kern said. “The Data Safety Monitor Board meeting will be held in the beginning of May and we expect to receive approval to start an accelerated enrollment of patients into the second cohort.”
Dancing helps prevent Parkinson’s disease, obesity, dementia, depression and anxiety, says Dr. Patricia Bragg, CEO of organic health company Bragg Live Food Products.“New studies show that dancing increases your memory and helps prevent a wide variety of diseases such as Alzheimer’s,” Bragg said in a press release.
Bragg’s father, Dr. Paul C. Bragg, was the originator of health stores in the United States, in 1912. For both father and daughter, dancing became a way of life.
Today, the 87-year-old Bragg sees herself as a crusader, born to carry on her father’s health movement, which pioneered many approaches that today would be considered “‘alternative medicine.”
“I have been dancing all of my life, and it’s not surprising to me that medical science is proving what I’ve known all along,” said Bragg.
Dancing has indeed been shown to help people with Parkinson’s recover balance and muscle control, as well as to help reduce the risk of Alzheimer’s dementia by 50 percent, which is expected to strike nearly 14 million Americans over the next 30 years.
“Think of the millions who can avoid this trauma simply by dancing,” said Bragg, the author of 10 best-selling “self-health” books.
According to a University of California Berkeley report, dancing has been shown to reduce depression, anxiety and stress and boost self-esteem. The New York Times also recently reported that dancing improves how the brain processes memory. Another study comparing the neurological effects of country dancing with those of walking and other activities suggested there might be something unique about social dancing.
In fact, dancing seems to increase cognitive acuity at all ages in a singular way, since they demand split-second decisions and exercise neuronal synapses. Dancing also helps keep the only neural connection to memory strong and efficient.
“My memories of dancing with Fred Astaire, Lawrence Welk, Arthur Murray and Gene Kelly are crystal-clear and so is my memory of the great time I had dancing last night,” said Bragg.
Most people know of Parkinson’s disease and have a good idea of its symptoms, but very few know much more than that about this progressive illness. Since April is Parkinson’s disease awareness month, we’ve put together some simple stats and facts that you can share near and far.
It’s a movement disorder.
Parkinson’s disease is a neurodegenerative disease whereby cells responsible for producing dopamine die off in the substantia nigra area of the brain. Dopamine is essential for movement as it acts as a transmitter for signals from the brain to other parts of the body.
Who found it? Parkinson’s disease was discovered by British surgeon Dr. James Parkinson in 1817.
How prevalent is it? Approximately one million people have Parkinson’s disease in the U.S. and there are around 50,000 new cases diagnosed eac1h year.
Most patients are middle-aged.
The average age of someone diagnosed with Parkinson’s disease is 56. Around 4 percent of Parkinson’s patients are diagnosed before the age of 50 and it’s considered young-onset if diagnosed before the age of 40.
When is it considered young-onset Parkinson’s disease?
It’s considered young-onset if diagnosed before the age of 40. The youngest recorded case of Parkinson’s was a 12-year-old patient.
How is it diagnosed?
There is no blood test or scan that can diagnose Parkinson’s disease. Doctors look for four classic symptoms of the disease before reaching a diagnosis: tremors, rigidity in the wrist and elbow joints, lack or slowness of movement, and an unstable posture.
It affects mostly men.
Parkinson’s disease is twice as likely to affect men than women.
There’s no known cause.
There is no known cause of Parkinson’s disease although a family history of the disease will increase your risk. Researchers think environmental factors such as smoking, pollution, heavy metals, medications and illegal drugs may be responsible for the onset of the disease. Head trauma, brain inflammation, and stroke have also been associated with the disease.
Parkinson’s is expensive.
Treating patients with Parkinson’s disease costs the U.S. around $25 billion a year. The average patient will need $2,500 worth of medication each year and therapeutic surgery could cost up to $100,000.
How do you treat it?
There is no cure for Parkinson’s disease but there are medications that can help patients with the symptoms. Patients can also undergo deep brain stimulation where electrical current is used to help block tremors and other movement symptoms of the disease.
There’s a correlation between Parkinson’s and depression.
Dopamine is also associated with mood as well as movement. It’s estimated that more than half of Parkinson’s disease patients suffer from depression and around 40 percent suffer from anxiety.
“We speculate that chronic emotional stress may cause dopaminergic cell loss in susceptible individuals and propose that functional somatic syndromes are commonly seen in patients with PD. Dopaminergic dysfunction with abnormalities in striato–thalamo–cortical brain circuits may be the shared underlying cause.”
You can’t see tremors in Paul Detlefsen’s hands now, but a decade ago, the outlook for this 43-year-old Parkinson’s disease patient looked a lot different.
“My symptoms were mostly in the right arm, sever tremors,” he said.
A recent article in the Harvard Gazette suggests dance as a potential treatment for neurodegenerative disorders such as Parkinson’s disease (PD).
Imaging studies have identified several brain regions involved in the complex, rhythmical, and coordinated movements that constitute dance. The motor cortex is — as with other kinds of voluntary movement — involved in planning, controlling, and executing dance moves.
Prepare for Your Hospital Stay Worksheet — Information regarding medications, symptoms and advanced directives in preparation for your hospital stay. Also included is a list of what to inform, ask and know during your hospitalization.
By The Michael J. Fox Foundation for Parkinson’s ResearchDo you know anyone who has Parkinson’s disease (PD)? It’s likely – the neurodegenerative disease affects one in 100 people over the age of 60, and more than 5 million people worldwide. Today, medicines exist to alleviate motor symptoms of the disease, but currently there are no treatments that can slow or stop its progression.
Researchers believe Parkinson’s results from a combination of both genetic and environmental factors, and, in recent years, scientists have discovered a number of genetic mutations associated with Parkinson’s. In about one percent of PD cases, the disease can be linked to a mutation in a gene called LRRK2.
While that may sound like a small number, the percentage is much higher in certain populations. In the Ashkenazi Jewish population, the mutation is responsible for 15 to 20 percent of PD cases. It is important to note that not everyone with a LRRK2 mutation will go on to develop Parkinson’s. But researchers believe that learning more about the genetics of Parkinson’s by studying those with and without the disease can help drive progress toward new treatments for everyone with PD.
A global study called the Parkinson’s Progression Markers Initiative (PPMI) launched efforts earlier this year to learn more about the genetics of PD. Families that carry a LRRK2 mutation have a vital role to play in this study, and there’s an easy way to be involved. The study is seeking volunteers to complete a brief survey to determine if they may be eligible to receive genetic counseling and testing of the LRRK2 gene at no cost.
By and large, Parkinson’s has not been considered to be a genetic disease. The majority of cases are called idiopathic, which simply means that we don’t know what caused the disease. In fact, only about 10 percent of PD cases have been linked to a genetic cause. Mutations in the LRRK2 gene are the most common cause of PD in this relatively small group, representing one to two percent of total Parkinson’s cases.
However, for people of certain ethnic backgrounds — Ashkenazi Jewish, North African Arab Berbers and Basque — mutations in LRRK2 account for a much greater number of PD cases than in the general population. While estimates vary, it is believed that changes in LRRK2 (predominantly the mutation scientists know as G2019S) account for 15 to 20 percent of cases in Ashkenazi Jews and about 40 percent of cases in North African Arab Berbers. Other genetic changes in LRRK2 that increase the risk of Parkinson’s disease have been found in additional populations, such as in Asians of Chinese descent. It remains an active area of research to find all the genetic changes in LRRK2 that may lead to Parkinson’s disease.
Measuring a particular blood protein might help doctors easily distinguish Parkinson’s disease from some similar disorders, a new study suggests.
The potential blood test is “not ready for prime time,” Parkinson’s disease experts said. But, it marks progress in the quest for an objective way to diagnose Parkinson’s and similar conditions known as atypical parkinsonian disorders, they noted. Read more
Life expectancy for people with Parkinson’s who receive proper treatment is often about the same as for the general population. Early detection is the key to reducing complications that can shorten your life. If you suspect that you or a loved one may have Parkinson’s disease, see your doctor right away.
Parkinson’s patients and others suffering debilitating tremors could be cured of their shaking using a new ultrasound machine which targets their brain cellsDoctors at Imperial College Healthcare NHS Trust have treated the first patients using the new technique which avoids the need for invasive brain surgery.
Squalamine, a chemical compound found in dogfish sharks, has the potential to reduce the formation of toxic proteins related to the development of Parkinson’s disease, new research suggests
Published in the Proceedings of the National Academy of Sciences, the study reveals that squalamine halted the buildup and toxicity of the protein alpha-synuclein (α-synuclein) in roundworm models of Parkinson’s disease and human neuronal cells.
Read more http://www.telegraph.co.uk/science/2017/01/16/dogfish-shark-extract-could-help-treat-parkinsons-disease-scientists/
The 100 trillion or so bacteria in our guts are important players in our normal biological processes and in protection against disease. Researchers have begun exploring possible imbalances in some bacteria levels in people with Parkinson’s and how those differences may lead to disease onset or progression. While this area of investigation is still fairly new, the field has some promising leads.
Vitamin B3 (niacin) was found to boost levels of a compound called NAD that generates energy and repairs DNA, according to new research that suggests boosting Vitamin B3 could keep Parkinson’s disease (PD) at bay.
Parkinson’s declines slowly, and not over hours, days or weeks. If PD symptoms worsen precipitously over a short period of time, then it is critical to search for secondary causes for these worsening symptoms. Potential causes for worsening Parkinson’s symptoms may include medication changes (which may be intentional changes or due to medication error), infections (such as a urinary tract infection, cold or flu), other medical problems (e.g., dehydration, problems with the heart, lungs, kidneys, liver, etc.), and/or stress, sleep deprivation, etc. read more http://www.pdf.org/en/parkinson_briefing_secrets_myths_question_answer
The National Parkinson Foundation (NPF) runs a toll-free Helpline, 1-800-4PD-INFO, (473-4636) The lifesaving NPF Helpline, launched in 2010, is staffed by a team of patient-focused nurses, social workers and therapists who answer calls about Parkinson’s disease (PD) in English and in Spanish Monday through Friday from 9 a.m. to 5 p.m. EST.
“NPF’s Helpline links our groundbreaking research to improve the lives of people with Parkinson’s today directly with the community we serve,” I know this first hand because the Helpline has made a difference in the life of my mother, who is living with Parkinson’s.” –John Kozyak, NPF’s Chairman of the Board. ”
“We’re more than just an information line. We truly care about the people we serve and that’s the key to our success, Whether you have yet to receive a diagnosis, are recently diagnosed with Parkinson’s, or caring for a family member with the disease, we are here to help you understand your condition, your care, and the latest research on how patients can live their best lives with Parkinson’s. We spend as much as 45 minutes on calls with those who have been recently diagnosed – more than three times the average – because we can really make a difference.” – Adolfo Diaz, NPF’s Director of Patient Services who manages the Helpline.”
NPF’s Helpline Specialists help callers locate resources in their area, as well as send a customized informational packet after the call. The NPF packets arm people with Parkinson’s and their families with helpful information on preparing for an appointment with their general practitioner or movement disorder specialist. People with Parkinson’s disease, their care partners and families are invited to call to receive emotional support and referrals to health professionals and community resources. A wide variety of helpful NPF publications and the Aware in Care kit are also available for order through the Helpline.
NPF also has an online video series called, “Ask the Helpline,” where our PD Specialists answer the most frequently asked questions including: why exercise is important, what role a movement disorder specialist plays and how the role of caregiver changes over time.
A new investigational drug originally developed for type 2 diabetes is being readied for human clinical trials in search of the world’s first treatment to impede the progression of Parkinson’s disease, following publication of research findings today in the journal Science Translational Medicine. More
A drug initially designed to treat diabetes may be a breakthrough treatment for Parkinson’s disease. After decades of disappointment, could MSDC-0160 be the drug researchers have been searching for? More
This post is about experimental drugs and treatments, Under absolutely no circumstances should anyone reading this consider it medical advice. These are novel results that need to be replicated and verified before being considered gospel. Before considering or attempting any change in your treatment regime, please consult with your doctor or neurologist.
The natural sweetener mannitol, a common component of sugar-free gums and candies, may hold potential for Parkinson’s disease (PD) according to a study, funded in part by the Parkinson’s Disease Foundation, in the June 14, 2013 issue of The Journal of Biological Chemistry. In this initial study, the compound not only improved PD-like symptoms in fruit flies, but also reduced harmful levels of alpha-synuclein (the hallmark of PD) in the brains of fruit flies and mice.
The Israeli scientists were interested in the ability of Mannitol to inhibit the formation of alpha synuclein aggregates (clumps of the protein that is associated with Parkinson’s disease). Chemicals similar to Mannitol have exhibited protein destabilizing properties, so it was an interesting idea to test.
The researchers used different concentrations of mannitol and added it to a solution of alpha-synuclein. They left this concoction shaking for 6 days (at 37°C) and then assessed the levels of aggregation. Curiously the low levels of Mannitol had the strongest inhibitory effect, while the higher concentrations had no effect. The researchers repeated the experiments and found similar results.
Given this success, they turned their attention to an animal model of alpha synuclein: a genetically engineered fly that produces a lot of alpha synuclein. They found that Mannitol treated flies had significantly less alpha synuclein aggregation in their brain than untreated flies. This study was then repeated in genetically engineered mice (that produce too much alpha synuclein) and guess what? They found the same results.
These results led the scientists to suggest that “mannitol administration in combination with other drugs could be a promising new approach for treating PD and other brain-related diseases such as Alzheimer disease”.
A warning regarding Mannitol
Before you rush out and start loading up on Mannitol there are a few things you should know about it.
It is used medically, usually to treat increased pressure within the skull.
It should not be abused, however, as it can have an osmotic effect (in particular, attracting water from the intestinal wall). Consumed in excess, it will cause diarrhea, abdominal pain, and excessive gas.
In addition to intestinal problems, Mannitol has also been associated with worsening heart failure, electrolyte abnormalities, or low blood volume. We also do not know what effect it may have on absorption of L-dopa and other Parkinson’s disease medications.
Haiyan Zhang, Innovation Director at Microsoft Research Cambridge, has taken part in the BBC’s The Big Life Fix challenge which asks young technologists to use their skills to help others.
Her task was to find a way to help 29-year-old Emma Lawton, who is a graphics designer, to improve her writing and drawing skills after this was negatively impacted by her Parkinson’s Disease diagnosed three years ago.
Whatever movement of the wrist is performed, the bowl of the spoon remains horizontal and keeps the food in place.
The material used is lightweight and strong. A key characteristic is the spoon’s affordability.
There are no electrical components or batteries, making it carry anywhere and to clean.
ELISPOON is a product designed and built to ease the life of the users and their love.
Two graduates from Israel’s Technion developed a spoon that their child with motor co-ordination problems could use without spilling its contents. Now anyone can buy it. Useful also for the elderly or anyone suffering from tremor
An Internet forum is a discussion area on a website. Website members can post discussions and read and respond to posts by other forum members. A forum can be focused on nearly any subject and a sense of an online community, or virtual community, tends to develop among forum members. A forum usually allows all members to make posts and start new topics.
Start a discussion or ask a question by starting here.
Recent advances in neuroscience have suggested that exercise-based behavioral treatments may improve function and possibly slow progression of motor symptoms in individuals with Parkinson disease (PD). The LSVT (Lee Silverman Voice Treatment) Programs for individuals with PD have been developed and researched over the past 20 years beginning with a focus on the speech motor system (LSVT LOUD) and more recently have been extended to address limb motor systems (LSVT BIG).
A new drug for levodopa-induced dyskinesia — involuntary, uncontrolled movements that can develop with long-term use of levodopa combined with a prolonged course of Parkinson’s disease (PD) — is one step closer to potentially reaching market.
A new project for the early detection of Parkinson’s disease with strongly magnetized xenon gas has been initiated at FMP. The team led by physicist Leif Schröder has received a three-year grant from the Michael J. Fox Foundation for Parkinson’s Research. Read more
Results from Phase 1, Phase 2a and preclinical studies of CVT-301, an inhaled form of levodopa, have been featured in the current edition of Science Translational Medicine. Acorda Therapeutics, Inc. (NASDAQ: ACOR) is developing CVT-301 for the treatment of OFF periods in people with Parkinson’s disease (PD).
Information and research about Parkinson’s Disease is changing quickly. Depending on information that is more than a few years old is not advised.
We are not endorsing or guaranteeing the accuracy of any of the supplied links. We have not created, reviewed (or even read) all of the educational material referenced. You may find outdated, false of contradictory information.
You may want to find the material(s) that would be useful to you and/or your patients and ask a doctor familiar with PD to review them before handing them out.
PDF offers a variety of educational publications and programs for people with Parkinson’s, their caregivers and families and allied health professionals. These materials can help answer questions about Parkinson’s disease symptoms, medications, medical care, exercise and nutrition, among other issues.
You can download all materials by using the links below and to the left. You can also order most of these materials online free of charge, for yourself or, in bulk for your practice, hospital or support group.
Parkinson’s disease (PD) is a movement disorder. In people with PD, a vital chemical in the brain called dopamine is gradually reduced. This brings on symptoms of tremor, slowness in movement, stiff limbs, and walking or balance problems.
These Parkinson’s disease (PD) resources will help you find more information and connect with others living with the condition. Many of these sites will direct you to the latest Parkinson’s disease news and research, as well as opportunities to get involved with local chapters and organizations.
Parkinson’s disease is an unexpected- and unwanted- twist and turn in your life journey. Like any journey there is uncertainty about what lies ahead, how things will change or where your life with PD will take you. (more…)